Applied Therapeutics, Inc. financial data

Symbol
APLT on Nasdaq
Industry
Pharmaceutical Preparations
Location
545 Fifth Avenue, Suite 1400, New York, NY
State of incorporation
DE
Fiscal year end
December 31
Latest financial report
10-K - Q4 2024 - Apr 15, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 176 % +113%
Debt-to-equity 133 %
Return On Equity -209 % -116%
Return On Assets -89.5 % +67.6%
Operating Margin -22.9K %

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 142M shares +33.7%
Common Stock, Shares, Outstanding 137M shares +61.7%
Entity Public Float 478M USD +648%
Common Stock, Value, Issued 35K USD +338%
Weighted Average Number of Shares Outstanding, Basic 140M shares +65.6%
Weighted Average Number of Shares Outstanding, Diluted 140M shares +65.6%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax 455K USD
Research and Development Expense 48.7M USD -9.57%
General and Administrative Expense 56M USD +172%
Operating Income (Loss) -104M USD -61.6%
Nonoperating Income (Expense) -1.33M USD +97.6%
Net Income (Loss) Attributable to Parent -106M USD +11.8%
Earnings Per Share, Basic -0.76 USD/shares +46.5%
Earnings Per Share, Diluted -0.76 USD/shares +46.5%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 79.4M USD +59.1%
Cash, Cash Equivalents, and Short-term Investments 22.9M USD -58.9%
Other Assets, Current 461K USD +6.71%
Assets, Current 83.6M USD +53.8%
Operating Lease, Right-of-Use Asset 2.79M USD +525%
Assets 86.7M USD +58.1%
Accounts Payable, Current 4.43M USD +154%
Contract with Customer, Liability, Current 212K USD -68.2%
Liabilities, Current 27.3M USD -61.7%
Operating Lease, Liability, Noncurrent 2.39M USD +6187%
Liabilities 29.7M USD -58.8%
Retained Earnings (Accumulated Deficit) -574M USD -22.5%
Stockholders' Equity Attributable to Parent 57M USD
Liabilities and Equity 86.7M USD +58.1%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -18.9M USD -171%
Net Cash Provided by (Used in) Financing Activities 115M USD
Net Cash Provided by (Used in) Investing Activities 13.9M USD +45.6%
Common Stock, Shares Authorized 250M shares +25%
Common Stock, Shares, Issued 137M shares +61.7%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 96.6M USD +1443%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 79.4M USD +59.1%
Deferred Tax Assets, Valuation Allowance 181M USD +19.5%
Deferred Tax Assets, Gross 182M USD +20%
Operating Lease, Liability 2.8M USD +499%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -106M USD +11.8%
Lessee, Operating Lease, Liability, to be Paid 3.92M USD +701%
Operating Lease, Liability, Current 406K USD -5.36%
Lessee, Operating Lease, Liability, to be Paid, Year Two 803K USD +3391%
Lessee, Operating Lease, Liability, to be Paid, Year One 787K USD +76.5%
Operating Lease, Weighted Average Discount Rate, Percent 0.15 pure +117%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 1.12M USD +5005%
Lessee, Operating Lease, Liability, to be Paid, Year Three 803K USD
Deferred Tax Assets, Operating Loss Carryforwards 115M USD +22.1%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10M shares 0%
Unrecognized Tax Benefits 0 USD
Lessee, Operating Lease, Liability, to be Paid, Year Four 823K USD
Additional Paid in Capital 631M USD +39.8%
Preferred Stock, Shares Outstanding 0 shares
Deferred Tax Assets, Net of Valuation Allowance 870K USD +526%
Share-based Payment Arrangement, Expense 15.6M USD +112%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%